BR112023019056A2 - Métodos para tratar doenças oculares usando variantes de aav2 que codificam aflibercepte - Google Patents
Métodos para tratar doenças oculares usando variantes de aav2 que codificam aflibercepteInfo
- Publication number
- BR112023019056A2 BR112023019056A2 BR112023019056A BR112023019056A BR112023019056A2 BR 112023019056 A2 BR112023019056 A2 BR 112023019056A2 BR 112023019056 A BR112023019056 A BR 112023019056A BR 112023019056 A BR112023019056 A BR 112023019056A BR 112023019056 A2 BR112023019056 A2 BR 112023019056A2
- Authority
- BR
- Brazil
- Prior art keywords
- aav2
- methods
- amino acid
- acid sequence
- capsid protein
- Prior art date
Links
- 241000702423 Adeno-associated virus - 2 Species 0.000 title 1
- 208000030533 eye disease Diseases 0.000 title 1
- 108090000565 Capsid Proteins Proteins 0.000 abstract 3
- 102100023321 Ceruloplasmin Human genes 0.000 abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 208000022873 Ocular disease Diseases 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 241000702421 Dependoparvovirus Species 0.000 abstract 1
- 229960002833 aflibercept Drugs 0.000 abstract 1
- 108010081667 aflibercept Proteins 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163180646P | 2021-04-27 | 2021-04-27 | |
| PCT/US2022/071937 WO2022232790A1 (en) | 2021-04-27 | 2022-04-26 | Methods of treating ocular diseases using aav2 variants encoding aflibercept |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023019056A2 true BR112023019056A2 (pt) | 2024-01-16 |
Family
ID=81984711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023019056A BR112023019056A2 (pt) | 2021-04-27 | 2022-04-26 | Métodos para tratar doenças oculares usando variantes de aav2 que codificam aflibercepte |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240197915A1 (https=) |
| EP (1) | EP4329721A1 (https=) |
| JP (1) | JP2024515459A (https=) |
| KR (1) | KR20240005764A (https=) |
| CN (1) | CN117222400A (https=) |
| BR (1) | BR112023019056A2 (https=) |
| CA (1) | CA3215855A1 (https=) |
| MX (1) | MX2023012410A (https=) |
| WO (1) | WO2022232790A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK4364724T3 (da) | 2018-05-10 | 2025-12-22 | Regeneron Pharma | Formuleringer med høj koncentration af VEGF-receptorfusionsprotein |
| EP3886946A1 (en) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| KR20260005446A (ko) | 2024-07-03 | 2026-01-12 | 김성훈 | 김치 제조 장치 |
| KR20260006393A (ko) | 2024-07-04 | 2026-01-13 | 김성훈 | 가정용 김치 제조 장치 |
| WO2026019885A1 (en) * | 2024-07-16 | 2026-01-22 | Adverum Biotechnologies, Inc. | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105755044A (zh) | 2011-04-22 | 2016-07-13 | 加利福尼亚大学董事会 | 具有变异衣壳的腺相关病毒病毒体及其使用方法 |
| AU2017257169B2 (en) * | 2016-04-29 | 2021-07-08 | Adverum Biotechnologies, Inc. | Evasion of neutralizing antibodies by a recombinant adeno-associated virus |
| ES2840059T3 (es) * | 2016-06-16 | 2021-07-06 | Adverum Biotechnologies Inc | Tratamiento de la DMRE mediante el uso de la variante AAV2 con aflibercept |
| EP4653536A3 (en) | 2017-03-17 | 2026-02-25 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression |
| CA3147843A1 (en) * | 2019-09-11 | 2021-03-18 | Mehdi Gasmi | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept |
| WO2021050094A1 (en) | 2019-09-11 | 2021-03-18 | Adverum Biotechnologies, Inc. | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept |
| HRP20260137T1 (hr) | 2019-09-11 | 2026-03-13 | Adverum Biotechnologies, Inc. | Liječenje očnih neovaskularnih bolesti upotrebom aav2 varijanti koje kodiraju aflibercept |
-
2022
- 2022-04-26 BR BR112023019056A patent/BR112023019056A2/pt unknown
- 2022-04-26 MX MX2023012410A patent/MX2023012410A/es unknown
- 2022-04-26 KR KR1020237040171A patent/KR20240005764A/ko active Pending
- 2022-04-26 CN CN202280030462.0A patent/CN117222400A/zh active Pending
- 2022-04-26 WO PCT/US2022/071937 patent/WO2022232790A1/en not_active Ceased
- 2022-04-26 US US18/554,965 patent/US20240197915A1/en active Pending
- 2022-04-26 JP JP2023558203A patent/JP2024515459A/ja active Pending
- 2022-04-26 CA CA3215855A patent/CA3215855A1/en active Pending
- 2022-04-26 EP EP22729004.6A patent/EP4329721A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3215855A1 (en) | 2022-11-03 |
| US20240197915A1 (en) | 2024-06-20 |
| JP2024515459A (ja) | 2024-04-10 |
| WO2022232790A1 (en) | 2022-11-03 |
| EP4329721A1 (en) | 2024-03-06 |
| CN117222400A (zh) | 2023-12-12 |
| MX2023012410A (es) | 2023-10-31 |
| KR20240005764A (ko) | 2024-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023019056A2 (pt) | Métodos para tratar doenças oculares usando variantes de aav2 que codificam aflibercepte | |
| BR112022004027A2 (pt) | Métodos para tratar doenças neovasculares oculares usando variantes de aav2 que codificam aflibercepte | |
| JP2020510428A5 (https=) | ||
| PH12020550094A1 (en) | Adeno-associated virus variant capsids and methods of use thereof | |
| MX2024009478A (es) | Métodos para tratar enfermedades neovasculares oculares con variantes de aav2 que codifican aflibercept | |
| MX2020005451A (es) | Capsides variantes de virus adenoasociados y uso para inhibir la angiogenesis. | |
| AR124119A2 (es) | Partículas virales modificadas y usos de estas | |
| PH12021552638A1 (en) | Compositions useful for treatment of pompe disease | |
| UY38881A (es) | Métodos de tratamiento de enfermedades neovasculares oculares utilizando variantes de aav2 que codifican aflibercept | |
| CL2020000295A1 (es) | Métodos de terapia génica del factor viii (fviii) | |
| WO2001016330A3 (en) | Prevention of affections associated with porcine circovirus-2 | |
| RU2014150340A (ru) | Лечение amd с применением экспессируемого aav sflt-1 | |
| MXPA02011545A (es) | Virus del sindrome respiratorio y reproductor porcino (peesv), vacuna recombinante para el virus de la viruela. | |
| MX2023006694A (es) | Tratamiento de la enfermedad de danon. | |
| PE20220930A1 (es) | Composiciones utiles en el tratamiento de leucodistrofia metacromatica | |
| RU2019103488A (ru) | Способы и композиции для лечения нарушений и заболеваний, связанных с rdh12 | |
| MX2024010002A (es) | Metodo para reducir la fluctuacion del cst en amd neovascular mediante un virus adenoasociado recombinante | |
| AR122404A1 (es) | Variantes de cápside y usos de las mismas | |
| MX2024010100A (es) | Virus adenoasociado recombinante con polipeptidos de la capside del vaa modificados | |
| BR112022019729A2 (pt) | Repetição terminal invertida (itr), vetor de ácido nucleico, partícula de vírus adenoassociado recombinante, composição farmacêutica e métodos de entrega de um ácido nucleico e de prevenção ou tratamento de uma doença | |
| PE20212072A1 (es) | Composiciones utiles en el tratamiento de la enfermedad de krabbe | |
| BR112022003206A2 (pt) | Métodos para tratar doenças neovasculares oculares usando variantes de aav2 que codificam aflibercepte | |
| ZA202409276B (en) | Aav vector encoding diamine oxidase and uses thereof | |
| AR133185A1 (es) | Métodos para tratar enfermedades neovasculares oculares usando variantes de aav2 que codifican aflibercept | |
| AR119955A1 (es) | Métodos de tratamiento de enfermedades neovasculares oculares utilizando variantes de aav2 que codifican aflibercept |